Keywords
Adolescent and young adult; Ewing sarcoma; Toxicity; VIDE; Chemotherapy
Abstract
Vincristine, ifosfamide, doxorubicin and etoposide (VIDE) is an intensive multiagent induction chemotherapy regimen used in the treatment of Ewing and other sarcoma, most often in children and younger adolescents. Its safety and tolerability in Adolescent and Young Adult (AYA) patients is not well documented. VIDE in this setting is novel, with only two Australian non-paediatric institutions adopting its use. This study aims to describe the experience of treating AYA sarcoma patients with VIDE at one of these two institutions, including an assessment of treatment-related adverse effects. Data from all sarcoma patients treated at Royal Prince Alfred Hospital and subsequently Chris O’Brien Lifehouse from 2013 to 2017 were analysed retrospectively. Assessment of VIDE administration, toxicity, and hospital length of stay was made from review of prescribing charts, medical records, and pathology results during treatment. Over this period, 13 patients aged 16 to 43 were treated with 74 cycles of VIDE. The most common toxicities were neutropenia (42%), anaemia (24%) and febrile neutropenia (41%). Dose modification occurred in 64% of cycles. No treatment-related deaths occurred. Even in patients subsequently admitted with febrile neutropenia, median total length of inpatient stay per cycle was 7 nights. VIDE chemotherapy in the AYA population is associated with frequent haematologic adverse events but acceptable tolerability and safety. Our experience demonstrates the feasibility of treating patients with VIDE in an adult oncology institution.
Citation
Lau B, Grimison P and Bhadri V. Tolerability and Safety of Vincristine, Ifosfamide, Doxorubicin and Etoposide in Adolescent and Young Adult Patients with Ewing Sarcoma. SM J Sarcoma Res. 2019; 3(1): 1013.